Liver Diseases  >>  Myrbetriq (mirabegron)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myrbetriq (mirabegron) / Astellas
NCT01579461: A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Completed
1
32
Europe
mirabegron, YM178
Astellas Pharma Europe B.V.
Pharmacokinetics, Healthy Subjects, Mild and Moderate Hepatic Impairment
04/09
04/09

Download Options